Compare BAOS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAOS | APRE |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 10.8M |
| IPO Year | 2020 | 2019 |
| Metric | BAOS | APRE |
|---|---|---|
| Price | $0.24 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.73 |
| AVG Volume (30 Days) | ★ 4.6M | 143.1K |
| Earning Date | 04-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.55 |
| 52 Week High | $5.21 | $1.69 |
| Indicator | BAOS | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 47.94 |
| Support Level | N/A | $0.70 |
| Resistance Level | $0.36 | $0.79 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 14.75 | 33.94 |
Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.